<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Renal accumulation of AGEs may contribute to the progression of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the effect of <z:chebi fb="0" ids="8774">ramipril</z:chebi> (a pure <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi>) and AVE7688 (a dual inhibitor of ACE and neutral endopeptidase) on renal accumulation of the advanced glycation end-product (AGE) 3-deoxyglucosone-<z:chebi fb="0" ids="20432">imidazolone</z:chebi>, carboxymethyllysine (<z:mp ids='MP_0005481'>CML</z:mp>) and pentosidine, and on clearance of <z:mp ids='MP_0005481'>CML</z:mp> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Male <z:chebi fb="3" ids="16646">Zucker</z:chebi> diabetic fatty rats (ZDF, Gmi-fa/fa) rats were treated from age 10 to 37 weeks with <z:chebi fb="0" ids="8774">ramipril</z:chebi> (1 mg.kg(-1).day(-1)), AVE7688 (45 mg.kg(-1).day(-1)) or without drug </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="8774">Ramipril</z:chebi> and AVE7688 reduced <z:mp ids='MP_0002871'>albuminuria</z:mp> by 30 and 90%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: ZDF rats showed increased renal accumulation of the AGE subtypes 3-deoxyglucosone-<z:chebi fb="0" ids="20432">imidazolone</z:chebi>, pentosidine and <z:mp ids='MP_0005481'>CML</z:mp> by about 40, 55 and 55%, respectively compared with heterozygous, non-diabetic control animals at the age of 37 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>AVE7688 but not <z:chebi fb="0" ids="8774">ramipril</z:chebi> attenuated the renal accumulation of 3-deoxyglucosone-<z:chebi fb="0" ids="20432">imidazolone</z:chebi>, pentosidine and <z:mp ids='MP_0005481'>CML</z:mp> and improved <z:mp ids='MP_0005481'>CML</z:mp> clearance in ZDF rats </plain></SENT>
<SENT sid="6" pm="."><plain>During glycation reactions in vitro, AVE7688 also demonstrated potent chelating activity and inhibited metal-catalysed formation of pentosidine and <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: Improved AGE clearance and direct inhibition of AGE formation by chelation may contribute to reduced accumulation of renal AGEs and to the nephroprotective effects of vasopeptidase inhibition in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>